Vyne Therapeutics Inc. · NASDAQ:VYNE

Vyne Therapeutics — Technical Presentation (July 2025)

9 slides from Vyne Therapeutics's technical presentation, Jul 30, 2025

  1. Slide 1: Repibresib (VYN201) Phase 2b Topline Results in Non-segmental Vitiligo

    Repibresib (VYN201) Phase 2b Topline Results Repibresib in Subjects with Non-segmental Vitiligo July 2025

  2. Slide 2: Forward Looking Statements and Important Notes

    Forward Looking Statements and Important Notes This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical development of VYNE’s product candidates and other stateme

  3. Slide 3: Repibresib (VYN201) Phase 2b NSV Trial Design

    Repibresib (VYN201) Phase 2b NSV Trial Design PART 1: Vehicle-controlled treatment period (24 weeks) Safety follow-up (4 weeks) Repibresib (VYN201) Gel 3% QD (N=41) W24 Primary endpoint W52 PART 2: Extension treatment period (28 weeks) Repibresib (VYN201) Gel 2% QD (N=43) Repibresib (VYN201) Gel 1%

  4. Slide 4: NDRs Characteristics (mITT)

    4 NDRs Characteristics (mITT) Repibresib 3% (N=41) Repibresib 2% (N=43) Repibresib 1% (N=46) Vehicle (N=47) Total (N=177) Age, mean (SD), y 49.0 (9.97) 51.4 (14.04) 48.6 (12.24) 51.7 (13.17) 50.2 (12.46) Age Category (years) ≤ 40 6 (14.6) 8 (18.6) 13 (28.3) 11 (23.4) 38 (21.5) > 40 to 65 34 (82.9) 3

  5. Slide 5: Subject Disposition & Treatment Discontinuation During 24-Week Period

    5 Corporate Events/PRs NDRs Repibresib 3% Repibresib 2% Repibresib 1% Vehicle Repibresib Overall Tota l Intent to Treat (ITT) 50 51 51 52 152 204 Modified Intent to Treat (mITT) 41 43 46 47 130 177 Per Protocol (PP) 40 43 46 47 129 176 Discontinued before Week 24 (mITT) 15 (36.6%) 13 (30.2%) 12 (26.

  6. Slide 6: Efficacy Endpoints: F-VASI50 (Primary) and F-VASI75 (Key Secondary)

    Proportion of Subjects Achieving F-VASI50 at Week 24* 6 Efficacy Endpoints: F-VASI50 (Primary) and F-VASI75 (Key Secondary) Variable Repibresib 3% (N=41) Repibresib 2% (N=43) Repibresib 1% (N=46) Vehicle (N=47) Subjects Achieving F-VASI50 at Week 24 Responder 8/41 (19.5%) 7/43 (16.3%) 8/46 (17.4%) 1

  7. Slide 7: Efficacy Endpoints: % Change from BL in F-VASI & T-VASI

    -50.0 -45.0 -40.0 -35.0 -30.0 -25.0 -20.0 -15.0 -10.0 -5.0 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 Percent Change from Baseline FVASI Treatment Week VYN201 3% VYN201 2% VYN201 1% Vehicle 7 Efficacy Endpoints: % Change from BL in F-VASI (Key Secondary) & T-VASI (Exploratory) Change from Baseline in F-V

  8. Slide 8: Additional Exploratory Analyses: F-VASI and T-VASI Change beyond Week 24

    -60.0 -55.0 -50.0 -45.0 -40.0 -35.0 -30.0 -25.0 -20.0 -15.0 -10.0 -5.0 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 Mean Percent Change from Baseline FVASI Treatment Week VYN201 3% VYN201 2% VYN201 1% Vehicle 8 Additional Exploratory Analyses: F-VASI and T-VASI Change beyond Week 24 Change from Ba

  9. Slide 9: Summary of Treatment Emergent Adverse Events ≥5% Frequency

    9 Summary of Treatment Emergent Adverse Events ≥5% Frequency Adverse Events ≥5% Frequency, n (%) 3% Repibresib (n=50) 2% Repibresib (n=51) 1% Repibresib (n=51) Vehicle (n=52) Total (n=204) Patients with at least one TEAE 40 (80.0%) 37 (72.5%) 39 (76.5%) 23 (44.2%) 139 (68.1%) Most common TEAEs by PT

VYNE Therapeutics — Technical Presentation (July 2025) on 6ix